H. Safran et al., PACLITAXEL AND CONCURRENT RADIATION FOR LOCALLY ADVANCED PANCREATIC AND GASTRIC-CANCER - G PHASE-I STUDY, Journal of clinical oncology, 15(3), 1997, pp. 901-907
Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting
toxicities, and potential antitumor activity of weekly paclitaxel with
concurrent radiation (RT) for locally advanced pancreatic and gastric
cancer. Patients and Methods: Thirty-four patients with locally advan
ced adenocarcinoma of the pancreas or stomach were studied. The initia
l dose of paclitaxel was 30 mg/m(2) by 3-hour intravenous (IV) infusio
n repeated every week for 6 weeks with 50 Gy RT. Doses were escalated
at 10-mg/m(2) increments in successive cohorts of three new patients u
ntil dose-limiting toxicity was observed. Results: The dose-limiting t
oxicities at 60 mg/m(2)/wk were abdominal pain within the RT field, na
usea, and anorexia. Of 23 patients with assessable disease, 11 (seven
with gastric, four with pancreatic cancer) had objective responses for
an overall response rate of 48%. Conclusion: Concurrent paclitaxel wi
th upper abdominal RT is well tolerated at dosages that have substanti
al activity. A phase II trial of neoadjuvant paclitaxel and RT at the
MTD of 50 mg/m(2)/wk is underway. (C) 1997 by American Society of Clin
ical Oncology.